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ABSTRACT 
Medoroga is a condition in which there is an excessive accumulation of 
Meda Dhatu in the body. Accumulation of Medo Dhatu in different parts of 
the body causes blockage of Strotsa which ultimately leads to poor 
nourishment of other Dhathus. Lack of exercises and Kaphavardhak Ahar 
Viharar are the two main causes of Medoroga. In modern times, way of life 
has changed drastically to quick nourishments and inactive tendencies 
throughout the world. Because of these factors, accumulation of Meda 
dhatu happens immensely. In Ayurveda, dyslipidemia is considered under 
Medoroga. Dyslipidemia is an emerging serious health abnormality 
associated with co-morbidities including CVD that continues to be the 
leading cause of death worldwide. It is characterized by an increase in 
cholesterol, triglycerides, LDL levels, and a decrease in HDL levels. The 
present study has been designed to compare the efficacy of Triphala Kwath 
and Trikatu capsules on various clinical parameters in the management of 
Medoroga w.s.r to dyslipidemia. Twenty patients fulfilling the inclusion 
criteria were randomly selected for the trial and put into two groups of ten 
patients each. Trikatu capsules were given to patients in group I and 
Triphla kwath with Madhu and Trikatu capsules in combination were given 
to patients of group II for 8 weeks. Patients were thoroughly assessed on 
various scientific parameters during the complete trial period. In group II, a 
significant (p<0.001) improvement was observed in subjective parameters 
and serum cholesterol, triglycerides, LDL, VLDL levels while in group I, a 
significant (p<0.001) improvement was observed in HDL only. It may 
affirmatively be construed from the study that the best impact of the trial 
drugs was observed with Triphala Kwatha with Madhu and Trikatu Capsule 
together (i.e. Group II). This combination therapy was most effective in 
reducing the overall lipid profile with substantial gains related to 
subjective as well as objective parameters without any adverse effects.  
 
INTRODUCTION
India is undergoing a rapid epidemiological 
transition with increasing population, economic 
wealth and urbanization,[1] however increase in 
adverse lifestyles such as smoking and tobacco use, 
nutritional habits with intake of unhealthy diet, and 
increasing sedentary lifestyle ultimately leads to 
non-communicable diseases, including coronary 
heart disease, cerebrovascular and peripheral 
artery diseases[2,3]. Even in rural areas of India non-
communicable diseases have become the leading 
cause of death[2,3]. Medoroga (Dyslipidemia) is a 
single contributory factor for many life style 
diseases. It is characterized by an unusual measure 
of lipids (triglycerides, cholesterol and fat 
phospholipids) in the blood. Lipids are the naturally 
occurring molecules which constitute the structural 
component of various cell membranes. Lipids have 
a normal property of Snehatwa (lubricity)[4]. 
According to Ayurveda, Medo Dhatu, Vasa and Majja 
Dhatu are the three components of out of seven 
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Dhatus that comprises human body. These 
additionally show same property of Snehatwa thus 
lipids can be corresponded with these three 
elements. They show regular highlights however 
each one of those are available at destinations and 
perform various capacities. Sneha offers 
chubbiness, lubricates every cell of the body and 
provides strength, energy to the body when in 
normal state[5], when it is in an upset state it causes 
Rasagata Snehavriddhi and leads to Medodushti 
(Dyslipidaemia)[5]. The depiction of Medoroga has 
been given in different classical texts. It results from 
various etiological factors, for example, defective 
eating regimen, doing no physical exercise, getting a 
charge out of day rest, and taking Kapha inciting 
diet and sugar rich eating routine. The etiological 
factors are Kapha and Meda Sadharmi Ansha in 
overabundance hence produce Kapha Bhuista 
Dosha Virddhi[6]. That Dosha Vridhi because of its 
very nature influences the Agni and producesAgni 
Vikriti. As an outcome, the Ama goes straight 
forward to Medodhatu and blends with Kapha at the 
tissue level and causes an increase in Meda Dhatu. 
This results in Srotasavrodha, channels of Dosha are 
blocked and thus Vata in the Kostha causes 
Jatharagni Sandhukashan, which results in food 
cravings and leads to over-intake of food 
consequentially leading toMedoroga[6]. "Infections 
and intricacies that happen in patients of Medoroga 
are difficult to treat, than those of patients who 
don't have Medoroga"[7]. There is no straight 
forward reference in Ayurveda that can be 
associated with dyslipidemia. Still, based on 
description of Medoroga, it can be correlated with 
Medoroga. Dyslipidemia incorporates hyper-
lipidemia and hyper lipoproteinemia which are 
caused because of abnormally raised degrees of 
lipoproteins in the blood[8]. These lipids incorporate 
phospholipids, cholesterol, cholesterol esters, and 
triglycerides. Lipoproteins are partitioned into 5 
classes based on thickness as (a) HDL (High-
thickness lipoprotein), (b) LDL (Low-thickness 
lipoprotein), (c) IDL (Intermediate thickness 
lipoprotein), (d) VLDL (Very low thickness 
lipoprotein), (e) chylomicrons. Dyslipidemia is one 
of the significant issues, which is characterized by 
the increased levels of either cholesterol, LDL 
cholesterol or triglycerides in the serum or both 
LDL and triglycerides and decrease in HDL in the 
serum that adds to atherosclerosis[8]. Athero-
sclerosis is the major risk factor for morbidity and 
mortality associated with Cardio-vascular Disease 
(CVD)[2,3]. Keeping in view the prevalence and 
intricacies of Medoroga, the present study has been 
designed to compare the efficacy of Triphala Kwath 
and Trikatu capsules on various clinical parameters 
in the management of Medoroga w.s.r to 
dyslipidemia. 
MATERIALS AND METHODS 
To fulfill all the aims and objectives of the 
study, the following materials and methods were 
used. 
Selection of the patients 
Patients were randomly selected from 
OPD/IPD of R.G.G.P.G. Ayurvedic College and 
Hospital, Paprola, Dist. Kangra (H.P.). A detailed 
history was obtained, physical examination was 
conducted and relevant investigations were carried 
out before enrolment of the study subjects. 
Total 20 patients were selected for the 
clinical trial of this research work. 
Grouping of Patients 
Twenty patients fulfilling the inclusion criteria 
were randomly selected for the trial and put into 
two groups of ten patients each.  
Group I patients were administered Trikatu 
capsules. 
Group II patients were administered Triphla kwath 
with Madhu and Trikatu capsules. 
Dose of Drugs and Route of Administration  
Triphla Kwatha 20ml b.i.d with one tsf Madhu 
Trikatu capsules 500mg b.i.d with water.  
Route of Administration- Oral 
Duration of Trial- 8 weeks 
Inclusion Criteria 
1. Diagnosed and confirmed cases of dyslipidemia 
based on investigations i.e.  
(a) Serum Cholesterol>200mg/dl and <300mg/dl 
(b) Serum Triglycerides>150mg/dl and <450mg/dl 
(c) Serum LDL>100mg/dl and <200mg/dl  
(d) Serum VLDL>30mg/dl and <100mg/dl 
(e) Serum HDL<40mg/dl and <20mg/dl 
2. Patients between the age group of 40-60 years of 
either sex who have fulfilled the criteria of 
objective and subjective parameters. 
Exclusion Criteria 
1. Patients not willing for the trial. 
2. All Medo Rogi presenting with complications 
like Prameha Pidika. 
3. Drug induced dyslipidemia. 
4. Patients having illness like TB, carcinoma, renal 
and liver disorders. 
5. Patients having history of MI and unstable 
angina. 
6. Patients below 40 and above 60years of age. 
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7. Patients with Serum Cholesterol>300mg/dl, 
Serum Triglycerides>450mg/dl, Serum HDL< 
20mg/dl, Serum LDL>200mg/dl, Serum VLDL> 
100mg/dl. 
Criteria for evaluation 
Assessment criteria 
 Clinical results were assessed based on 
subjective and objective parameters. Scoring 
system was adopted to assess subjective signs and 
symptoms. A special proforma was designed for 
assessment based on Ayurvedic principles and 
modern scientific knowledge. Patients were also 
inquired about any growing feeling of physical and 
mental well-being after the therapy.  
Subjective criteria 
It includes signs and symptoms described in 
Ayurvedic texts. These are the following: 
 Chala- Sphika- Udara -Stana 
 Kshudra Shwasa 
 Sandhi Shoola 
 Kshudha Atimatra 
 Pipasa Atiyoga 
 Nidradhikya 
 Javop rodha 
 Swedabadha 
 Daurgandhya 
Table1: Grading of symptoms 
Symptoms Grading 
Chal -sphik- udar- stanam (Movement of Body Parts)  
Absence of movement  
Little movement after fast activity  
Movement after mild activity  
Movement even on changing posture  
0 
1 
2 
3 
Kshudra Shwasa (Shortness of Breath)  
No shortness of breath  
Shortness of breath after hard physical exertion  
Shortness of breath after mild physical exertion  
Shortness of breath even at rest 
0 
1 
2 
3 
Sandhi Shool (Pain in Joints)  
No pain  
Mild pain of low intensity causing no disturbance in routine work  
Moderate pain occasionally hampering daily routine work  
Severe pain causing a definite interruption in routine work  
0 
1 
2 
3 
Kshudha Atimatra (Excessive Hunger)  
<2 Chapatis/meal  
2-4 Chapatis/meal  
4-6 Chapatis/meal  
 >6 Chapatis/meal 
0 
1 
2 
3 
Pipasatiyoga (Excessive Thirst)  
1.5 lit/day of fluid  
1.5-2 lit/day of fluid 
2-3 lit/day  
3 lit/day 
0 
1 
2 
3 
Nidradhikya (Excessive Sleep)  
6-8 Hrs/day  
8-10 Hrs/day  
10-12 Hrs/day  
>12 Hrs/day 
0 
1 
2 
3 
Javoparodha (Lassitude)  
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Fully active  
Hesitate to start work but once start, complete it  
Starts but not complete it  
Doesn’t have the drive, works under compulsion  
0 
1 
2 
3 
Swedabadha (Excessive Sweating)  
Normal perspiration  
Mild perspiration after doing exertion  
Heavy perspiration after doing little exertion  
Perspiration without exertion 
0 
1 
2 
3 
Daurgandhya (Bad Body Odour)  
Absence of odour  
Occasional bad odour  
Persistent bad odour  
Persistent bad odour, intolerable to the patient  
0 
1 
2 
3 
Objective Criteria 
 Lipid Profile 
 Body Mass Index (BMI), 
 Body weight 
 Skin Fold Thickness 
Investigation Based Criteria 
It mainly consists of lipid profile, and patient having 
deranged lipid value were included in the study i.e. 
Serum Cholesterol >200 mg/dl 
Serum Triglycerides>150 mg/dl 
Serum LDL>100 mg/dl 
Serum VLDL>30 mg/dl 
Serum HDL<40 mg/dl. 
Other Investigations 
1. Hb gm% 
2. TLC (Total leucocyte count) 
3. DLC (Differential leucocyte count) 
4. ESR (Erythrocyte sedimentation rate) 
5. FBS (Fasting blood sugar) 
6. Blood urea  
7. Serum creatinine 
8. SGOT 
9. SGPT 
10. Urine- routine and microscopy 
Selection of Drug 
Triphala Kwatha and Trikatu Capsules are 
the important prestigious formulations, which are 
successfully used from the ancient period. These 
formulations have been mentioned in various 
Ayurvedic classics like Chakradatta, Yoga 
Ratanakara, Sharangadhara Samhita and Vrinda 
Madhava. The reference of Triphala Kwatha with 
Madhuused in this trial was selected from Yoga 
Ratanakara for the management of Medoroga and 
Trikatu churna from Sushrut Sutrasthan. These 
drugs were prepared by Pharmacy experts of 
Charaka Rajkiya Ayurveda Pharmacy, Paprola, Dist 
Kangra H.P. as per G.M.P. norms. 
Table 2: Pharmacological Characters of Ingredients of Triphala Kwath [9] 
S.No Ingredients 
Botanical 
Name 
Family Rasa Guna Veerya Vipaka 
Dosha 
Karma 
1. Haritaki 
Terminalia 
chebula 
Retz. 
Combretaceae 
Pancharasa 
(Alavana 
Kashaya 
pradhana) 
Laghu, 
Ruksha 
Ushna Madhura Tridoshahar 
2. Bibhitaka 
Terminalia 
bellirica 
(Gaertn.) 
Roxb. 
Combretaceae Kashaya 
Ruksha, 
Laghu 
Ushna Madhura Tridoshahar 
3. Amalaki 
Emblica 
officinalis 
Gaertn. 
Euphorbiaceae 
Pancharasa 
(Alavana-
Amla 
pradhana) 
Laghu, 
Ruksha 
Sheeta Madhura Tridoshahar 
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Table 3: Pharmacological Characters of Ingredients of Trikatu Capsules [9] 
S.No Ingredients 
Botanical 
Name 
Family Rasa Guna Veerya Vipaka 
Dosha 
Karma 
1. Sonth 
Zingiber 
officinale 
Roscoe 
Zingiebraceae Katu 
Laghu 
Sanigdha 
Ushna Madhur 
Kaphvata 
Shamak 
2. Marich 
Piper 
nigrum L. 
Piperaceae Katu 
Laghu 
Sheeta 
Ushna Katu 
Vatkapha 
Shamak 
3. Pippali 
Piper 
longum L. 
Piperaceae Katu 
Laghu 
Sanigha 
Tikshna 
Anushanas
heeta 
Madhur 
Vatakapha 
Shamak 
OBSERVATION AND RESULTS 
Among 20 registered patients’ maximum patients i.e., 55% were in the age group of 40-50 years 
followed by 45% patients were in the age group of 50-60 yrs. On gender wise distribution majority of 
patients were females i.e. 75% and 25% of the patients were male. Housewives were predominant group of 
study than others i.e. 65%. 20% patients were in Govt job; 5% were in private job and 15% patients were 
engaged in business. 
Majority of the patients (70%) were used to consume mixed diet while rest i.e. 30% patients were 
taking vegetarian diet. Among 20 registered patients, maximum i.e. 65 % had excessive appetite, 35% had 
normal appetite. Out of 20 patients, 40% have Mridu Koshtha, 50% have Madhyam Koshtha, 10% have Krura 
Koshtha. Majority of the patients in both groups i.e. 80% had excessive sleep followed by 20% had sound 
and adequate sleep. Data showed that patients of Vatakaphaj Prakriti were maximum (75%), followed by 
Pittakaphaj Prakriti (25%). The effects of therapy on various subjective and objective parameters are given 
below from Table 4 to 8 and figure1 & 2. 
Table 4: Effect of Therapy on Subjective Symptoms 
S.No Symptoms Group Mean Score % 
Change 
SD+ SE+ ‘t’ ‘p’ Inter-group 
Comparison 
BT AT 
1 Chala Sphika 
Udara Stana 
Group-I 1.375 1 27% 0.518 0.183 2.049 0.080 t= 2.170 
p= 0.045 
Group-II 1.4 0.5 64% 0.568 0.18 5.014 <0.001 
2 Kshudra 
Shwasa 
Group-I 1.375 1 27% 0.518 0.183 2.049 0.080 t=2.573 
p=0.020 
Group-II 1.3 0.3 76% 0.667 0.211 4.743 0.001 
3 Sandhi Shoola Group-I 0.25 0.125 50% 0.354 0.125 1.000 0.351 t=-2.342 
p=0.032 
Group-II 1.5 0.6 60% 0.568 0.18 5.014 <0.001 
4 Kshudha 
Atimatra 
Group-I 1.5 1.25 16.66% 0.463 0.164 1.528 0.170 t=2.399 
p=0.029 
Group-II 1.3 0.6 53.84% 0.675 0.213 3.280 0.010 
5 Pipasa 
Atiyoga 
Group I 1.375 1.125 18.18% 0.463 0.164 1.528 0.170 t=2.412 
p=0.028 
Group II 1.3 0.4 69.23% 0.568 0.18 5.014 <0.001 
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6 Nidradhikya Group I 1.625 1.375 15.38% 0.463 0.164 1.528 0.170 t=2.762 
p=0.014 
Group II 1.2 0.6 50% 0.699 0.221 2.714 0.024 
7 Javoproda Group-I 0.5 0.125 60% 0.744 0.263 1.426 0.197 t= -2.347 
p=0.032 
Group-II 1.7 0.6 64% 0.568 0.18 6.128 <0.001 
8 Swedabadha Group-I 0.875 0.625 28% 0.463 0.164 1.528 0.170 t= 2.160 
p=0.046 
Group-II 0.8 0.1 87.50% 0.675 0.213 3.280 0.010 
9 Daurgandhya Group-I 1.375 1.125 18.18% 0.463 0.164 1.528 0.170 t=2.437 
p=0.027 
Group-II 1.3 0.5 61.50% 0.789 0.249 3.207 0.011 
Table 5: Effect Of Therapy on BMI 
S.No Category Group 
Mean Score % 
Change 
SD± SE± ‘t’ ‘p’ 
Inter-Group 
Comparison BT AT 
1. BMI 
Group-I 31.125 29.75 4.41% 2.106 0.744 2.434 0.045 t=2.138 
p=0.048 Group-II 29.8 27.7 7.04% 1.951 0.617 6.034 <0.001 
Table 6: Effect of Therapy on Body Weight 
S.No. Category Group 
Mean Score 
% 
Change 
SD± SE± ‘t’ ‘p’ 
Inter-Group 
Comparison 
BT AT 
1. Body Weight 
Group I 72.7 70.5 2.90% 2.37 0.838 4.968 0.002 t = 2.128 
p =0.049 Group II 72.42 68.3 5.68% 2.063 0.652 6.88 <0.001 
Table 7: Effect of Therapy on Skin Fold Thickness 
S.No Categories Group 
Mean Score 
% 
Change 
SD+ SE+ ‘t’ ‘p’ 
Inter group 
Comparison 
BT AT 
1 Bicep 
Group-I 2.95 2.68 9.1% 0.368 0.130 6.251 <0.001 t = 2.1 
p = 0.047 Group-II 2.89 2.34 19% 0.344 0.108 8.199 <0.001 
2 Tricep 
Group-I 3.2 2.987 9.3% 0.470 0.166 4.389 0.002 t=2.516 
p= 0.023 Group-II 3.04 2.48 18.42% 0.401 0.127 11.225 <0.001 
3 Suprailliac 
Group-I 5.66 4.9 13.4% 1.013 0.358 5.127 0.001 t=2.101 
p=0.052 Group-II 5.63 3.96 29.66% 0.885 0.279 13.19 <0.001 
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Table 8: Effect of Therapy on Serum Lipid Profile 
S.No 
Lipid 
Profile 
Group 
Mean Score 
% 
Change 
SD+ SE+ ‘t’ ‘p’ 
Inter group 
Comparison 
BT AT 
1 
Serum 
Cholesterol 
Group-I 240.75 211.75 12.04% 36.269 12.823 2.262 0.058 t=10.9 
p<0.001 Group-II 230.7 134.2 41.82% 31.43 9.94 9.708 <0.001 
2 
Serum 
Triglyceride 
Group-I 270.375 268.125 0.83% 28.085 9.93 0.227 0.827 t=18.2 
p<0.001 Group-II 296.875 143 51.60% 79 25.2 6.04 <0.001 
3 Serum LDL 
Group-I 95.5 87.87 7.9% 30.56 10.807 0.706 0.503 t=5.36 
p<0.001 Group-II 128.4 48.5 62.22% 28.7 9.1 8.70 <0.001 
4 Serum HDL 
Group-I 34.25 61.37 44.19% 7.7 2.7 -9.84 <0.001 t=10.7 
p<0.001 Group-II 33.2 37.2 10.75% 7 2.2 1.7 0.107 
5 Serum VLDL 
Group-I 38.25 36.25 5.2% 3.5 1.2 1.5 0.155 t=9.02 
p<0.001 Group - II 35.2 17.7 49.71% 6.819 2.156 8.1 <0.001 
Figure 1: Effect of Therapy on BMI, Body Weight and Skin Fold Thickness 
 
Figure1.*BT (Before Treatment), AT (After Treatment) 
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BMI Body Weight Bicep Tricep Suprailliac
Group I 31.125 29.75 72.7 70.525 2.95 2.6 3.2 2.98 5.66 4.9
Group II 29.8 27.7 72.42 68.3 2.89 2.34 3.04 2.48 5.63 3.96
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Figure 2: Effect of Therapy on Serum Lipid Profile 
 
Figure2.*BT (Before Treatment), AT (After Treatment), CHO (Cholesterol), TG (Triglycerides), LDL (Low 
Density Lipoproteins), HDL (High Density Lipoproteins), VLDL (Very Low-Density Lipoproteins) 
DISCUSSION 
In subjective parameters a highly significant 
(P<0.001) improvement was found in Chala Sphika 
Udara Stana, Sandhi Shoola, Pipasa Ati Yoga, Pipasa 
Ati Yoga, Javoprodha and significant improvement 
was found in Kshudra Shwasa, Kshudha Atimatra, 
Nidradhikya, Swedabadha and Daurgandhya in 
patients of Group II. While in Group I, insignificant 
improvement was found in the above mentioned 
subjective parameters as shown in Table 4. 
There was a statistically highly significant 
decrease (p<0.001) in BMI by 7.04% in group II. In 
group in only statistically significant (p=0.045) 
improvement i.e., 4.41% was observed as shown in 
Table 5. 
On intergroup comparison, statistically 
significant difference was found between the results 
of both the groups (p=0.048). There was a highly 
significant decrease (p<0.001) in weight by 5.68% 
in group II. In group I, statistically significant 
(p=0.002) improvement i.e., 2.90% was observed as 
shown in Table 6. 
On intergroup comparison, a significant 
difference was found between the results of both 
the groups (p=0.049).  
There was a highly significant decrease 
(p<0.001) in Skinfold Thickness of biceps by 19% in 
group II. In group I, only 9.1% decrease in Skinfold 
thickness of biceps was observed after the therapy 
which was statistically significant (p<0.001). On 
intergroup comparison, a significant difference 
between the results of both the groups (p=0.047). 
There was highly significant decrease (p<0.001) in 
Skinfold thickness of Triceps by 18.42% in group II. 
In group I, only 9.3% decrease in Skinfold thickness 
of Triceps was observed after the therapy which 
was significant (p=0.002). On intergroup 
comparison, a significant difference was found 
between the results of both the groups (p=0.023). 
There was a highly significant decrease (p<0.001) 
in skinfold thickness of suprailiac by 29.66% in 
group II. In group I, only 13.4% decrease in skinfold 
thickness of suprailiac was observed after the 
therapy which was significant (p=0.001). On 
intergroup comparison, there was no significant 
difference between the results of both the groups 
(p=0.052) as shown in Table 7 and fig. no. 1. 
Serum Lipid Profile 
There was a highly significant decrease 
(p<0.001) in serum cholesterol by 41.82% in group 
II. In group I, only 12.04% decrease in serum 
cholesterol was observed after the therapy which 
was not significant (p=0.058). On intergroup 
comparison, a highly significant difference was 
found between the results of both the groups 
(p<0.001). There was a highly significant decrease 
(p<0.001) in serum triglycerides by 51.60% in 
group II. In group I only 0.83% decrease in serum 
BT AT BT AT BT AT BT AT BT AT
CHO TG LDL HDL VLDL
Group I 240.75 211.75 270.3 268.12 95.5 87.8 34.25 61.37 38.25 36.25
Group II 230.7 134.2 294.5 143 128.4 48.5 33.2 37.2 35.2 17.7
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triglycerides was observed after the therapy which 
was not significant (p=0.827). On intergroup 
comparison, a highly significant difference was 
found between the results of both the groups 
(P<0.001). There was a highly significant decrease 
(p<0.001) in serum LDL by 62.22% in group II. In 
group I, only 7.9% decrease in serum LDL was 
observed after the therapy which was not 
statistically significant (p=0.503). On intergroup 
comparison, a highly significant difference was 
found between the results of both the groups 
(p<0.001). There was a significant increase 
(p=0.005) in serum HDL by 44.19% in group I. In 
group II, only 10.75% increase in serum HDL was 
observed after the therapy which was not 
significant (p=0.107). On intergroup comparison, a 
highly significant difference was found between the 
results of both the groups (p<0.001). There was a 
highly significant decrease (p<0.001) in serum 
VLDL by 49.71% in group II. Decrease by 5.2% in 
serum VLDL was observed in group 1 after the 
therapy which was not significant (p=0.155). On 
intergroup comparison, a significant difference was 
found between the results of both the groups 
(p<0.001). So, in group II, a highly significant 
(p<0.001) improvement was found in serum 
cholesterol, triglycerides, LDL, VLDL while in group 
I, a statistically highly significant (p<0.001) 
improvement was observed in HDL only as shown 
in Table 8 and figure 2. 
Insignificant results were found in the other 
parameters including TLC, DLC, ESR, FBS, Blood 
urea, Serum creatinine etc.  
The Inter-group comparison showed that 
Triphala Kwath with Madhu and Trikatu capsules in 
combination are more effective in dyslipidemia as 
compare to only single drug i.e., Trikatu capsules. 
The difference was statistically significant. Hence 
the study proved the efficacy of Triphala Kwath 
with Madhu and Trikatu capsules in combination 
with the symptomatology of Medoroga 
(Dyslipidemia). No side effects of Triphala Kwath 
with Madhu and Trikatu Capsules were reported as 
evident by the fact that no patient complained of 
any untoward symptom after the administration of 
drug.  
An ideal drug is the one that breaks the 
pathogenesis of the disease without producing any 
side effects. It is the total effect of all the ingredients 
that plays a vital role in the treatment of disease. In 
Medoroga, Vata and Kapha Doshas are involved 
along with Medodhatvagni mandya and Srotorodha. 
So, drugs used in the present study have Vatakapha 
Shamak, Deepana, Pachna, Srotoshodhna, and 
Medohar properties. Ingredients of present trial 
drugs i.e., Triphala Kwath and Trikatu capsules 
possess most of the above said properties which are 
desirable in an ideal Medohara drug. Triphala 
Kwatha contains drugs which are mainly Laghu, 
Ruksha Guna, Ushna Virya and Tridoshhara. Because 
of all these properties Triphala work as Medohara. 
Trikatu being Katu Rasa and Katu Vipaka, Ushna 
Virya and Laghu Ruksha Guna in nature just inverse 
to Medodhatu diminish the amount of Medodhatu in 
body. Madhu was used as Anupaan in the present 
study which potentiates the action of the drug. 
Because of Kashaya Rasa, Guru, Ruksha Guna it acts 
as Tridoshshamak and Medoghana. 
In the present study, a significant decrease 
in the total cholesterol, triglycerides, LDL and VLDL 
in Triphala Kwath with Madhu treated patients may 
be due to reduction in the absorption of 
cholesterol[10]. Oral administration of T. Chebula is 
reported to increase gastric emptying, which might 
be the reason for the decrease in the cholesterol 
absorption.[11] Drugs like Statins reduce LDL 
cholesterol by inhibiting HMG-CoA reductase in the 
liver. In our study, we have observed a reduction in 
the LDL cholesterol after Triphala Kwath with 
Madhuadministration. This may be due to, at lease 
in a part, the HMG-CoA reductase inhibitory action 
of Triphala[10]. 
It is claimed that Amalaki, one of the 
components of Triphala has various biological 
activities such as improves digestion[12], improves 
liver function and hepatoprotective[13]. Triphala has 
a balancing and rejuvenating effect on Vata, Pitta 
and Kapha. It is known that colon health is 
important. Proper regulation of the colon is a key to 
good health and longevity. Triphala works well as a 
colon cleanser and as a Rasayana (rejuvenation) for 
the colon. It is rich in fibers, which helps in 
digestion and regulation of bowel. Oral 
administration of Haritaki reported to increase 
gastric emptying, might be the reason of decreased 
absorption[11]. Most probably in the present study 
significant decrease in total cholesterol, 
Triglyceride and VLDL on the administration of 
Triphala Kwath may be due to reduction in 
absorption of cholesterol[14], results in improved 
liver functions[13], and decrease lipid 
peroxidation[15]. 
Madhu has been used both as food and 
medicine since ancient times. Madhu is a natural 
product that has been widely used for its 
therapeutic effects. Madhu as Anupana was used in 
the present study in combination with Triphala 
Kwath+Trikatu Capsules. As mentioned in Ayurveda 
Anupana (vehicle) is defined as the Pana which is 
taken immediately after Oushadhaanga (part of 
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medicine) and Oushadhi yoga (medicine 
formulation).[16] Anupana is defined as that, which 
enhances the properties of medicines along with it 
is taken. The mechanism by which Madhu exerts its 
effect as a natural product, may be due to its 
inhibitory effect on HMG–CoA reductase, which is 
very important in the production of cholesterol in 
the body, thereby effectively preventing hyper-
cholesterolemia, lowering LDL, triglycerides and 
increasing HDL levels. These actions effectively 
reduce the risk of major coronary events, including 
first and second heart attacks and stroke, in adults 
with unhealthy cholesterol levels[17]. 
Trikatu being of Katu, Tikta Rasa and 
Katuvipaka in nature[1], i.e., just opposite of 
Medodhatu, reduce the quantity of Medodhatu and 
also make the channels patent for easy conduction 
of nutrients for nourishment to following Dhatus. 
Several popular preparations of Trikatu have been 
mentioned by the Ayurvedic physicians for the 
treatment of many Kaphavataja diseases, including 
Agnimandya (poor digestion) and Ama (undigested 
food and its toxic byproducts). By therapeutic 
actions such as Deepana (appetizer), Pachana 
(digestive), Rukshana (producing dryness), Lekhana 
(producing sliminess), Karshana (extraction), and 
Shoshana (absorption), Tikshna (sharp), Laghu 
(light) and Sukshma (micro in size)[1], as a whole 
Trikatu reduces the quantity of Meda (which has the 
nature of Ama) and also makes the channels patent 
to carry on the nutrients to subsequent Dhatus as 
per the chronological order mentioned in Ayurveda. 
These pharmacological actions may be due to its 
chemical substance piperine which enhances the 
secretion of digestive juices and might catalyze the 
functions of enzymes in small intestine too, i.e. it 
helps in improving the function of Jatharagni 
(digestive fire). Improvement of Jatharagni 
function, in total, also helps in a finer disintegration 
of nutrients, in turn helping maximum absorption 
for nourishing rest of the Dhatus, and thus also 
facilitates the function of Bhutagnis (metabolism). 
In short, Trikatu acts against the deposition of lipids 
and thus helps clean the eventually blocked 
channels [18]. So, Trikatu Capsules probably acts by 
blocking the formation of different lipids or 
cholesterol at various stages in the biosynthetic 
pathway. Because it is a Rasayana, it may also cause 
an increase in the HDL cholesterol [18]. 
CONCLUSION 
It can be inferred from the present study 
that the best effects of the Trial drugs were seen 
with Triphala Kwatha with Madhu along with 
Trikatu Capsule together (Group II), which is most 
effective in reducing the overall lipid profile i.e., 
serum cholesterol, serum triglyceride, LDL, VLDL 
and increasing the HDL, with substantial gains 
related to subjective as well as objective parameters 
and that too, without any adverse effects. It can be 
concluded that Triphala Kwath with Madhu and 
Trikatu Capsules are effective in treating Medoroga 
(dyslipidemia) when given in combination.  
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